Submitted by financialtimes5061 in business
Two developers of drugs for inflammatory diseases are latest to disregard poor performance of newly listed companies
Submitted by financialtimes5061 in business
Two developers of drugs for inflammatory diseases are latest to disregard poor performance of newly listed companies